- Q1 2024 Seres Therapeutics Inc Earnings Call TranscriptMay 08, 2024$0.7494 (-32.49%)Earnings
- Q4 2023 Seres Therapeutics Inc Earnings Call TranscriptMar 05, 2024$1.06 (-7.02%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Q3 2023 Seres Therapeutics Inc Earnings Call TranscriptNov 02, 2023$0.9324 (-35.25%)Earnings
- Seres Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Seres Therapeutics Inc at Canaccord Genuity Growth Conference TranscriptAug 09, 2023
- Q2 2023 Seres Therapeutics Inc Earnings Call TranscriptAug 08, 2023$4.29 (-6.94%)Earnings
- Seres Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Seres Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Seres Therapeutics Inc Earnings Call TranscriptMay 09, 2023$5.57 (+0.18%)Earnings
- Seres Therapeutics Inc To Discuss SER-109 Approval Call TranscriptApr 27, 2023
- Q4 2022 Seres Therapeutics Inc Earnings Call TranscriptMar 07, 2023$5.4 (-1.64%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Seres Therapeutics Inc To Discuss Ser-109 Commercial Strategy Call TranscriptDec 08, 2022
- Q3 2022 Seres Therapeutics Inc Earnings Call TranscriptNov 02, 2022$8.19 (-9.50%)Earnings
- Q2 2022 Seres Therapeutics Inc Earnings Call TranscriptAug 03, 2022$4.45 (+8.54%)Earnings
- Seres Therapeutics Inc To Discuss 109 ECOSPOR IV Study Results Call TranscriptJun 07, 2022
- Q1 2022 Seres Therapeutics Inc Earnings Call TranscriptMay 04, 2022$4.72 (-2.48%)Earnings
- Q4 2021 Seres Therapeutics Inc Earnings Call TranscriptMar 01, 2022$7.4 (-7.56%)Earnings
- Seres Therapeutics Inc To Highlight Opportunities For Microbiome Therapeutics In Infection Protection Call TranscriptJan 31, 2022
- Seres Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Q3 2021 Seres Therapeutics Inc Earnings Call TranscriptNov 10, 2021$8.27 (+20.38%)Earnings
- Q2 2021 Seres Therapeutics Inc Earnings Call TranscriptAug 03, 2021$6.96 (-1.00%)Earnings
- Seres Therapeutics Inc To Discuss Topline Results From The Phase 2b ECO-RESET Study Evaluating SER-287 In Patients With Mild-To-Moderate Ulcerative Colitis Call TranscriptJul 22, 2021
- Seres Therapeutics Inc SER-109 Co-Commercialization License Agreement Call TranscriptJul 01, 2021
- Seres Therapeutics Inc SER-287 Clinical Data Update Call TranscriptJun 21, 2021
- Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- Q1 2021 Seres Therapeutics Inc Earnings Call TranscriptMay 04, 2021$21.48 (+5.55%)Earnings
- Q4 2020 Seres Therapeutics Inc Earnings Call TranscriptMar 02, 2021$19.62 (-4.85%)Earnings
- Seres Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Q3 2020 Seres Therapeutics Inc Earnings Call TranscriptNov 09, 2020$33.24 (-3.90%)Earnings
- Seres Therapeutics, Inc. - Special Call TranscriptAug 10, 2020
- Seres Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Seres Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2020
- Seres Therapeutics, Inc. - Special Call TranscriptMay 27, 2020
- Q1 2020 Seres Therapeutics Inc Earnings Call TranscriptMay 07, 2020$4.27 (+12.37%)Earnings
- Q4 2019 Seres Therapeutics Inc Earnings Call TranscriptMar 02, 2020$3.23 (+2.87%)Earnings
- Q3 2019 Seres Therapeutics Inc Earnings Call TranscriptNov 05, 2019$4.06 (+6.84%)Earnings
- Q2 2019 Seres Therapeutics Inc Earnings Call TranscriptAug 06, 2019$2.29 (-6.15%)Earnings
- Q1 2019 Seres Therapeutics Inc Earnings Call TranscriptMay 02, 2019$5.35 (-12.44%)Earnings
- Q4 2018 Seres Therapeutics Inc Earnings Call TranscriptMar 06, 2019$6.12 (-3.62%)Earnings
Seres Therapeutics Inc SER-109 Co-Commercialization License Agreement Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Seres Therapeutics Business Update Conference Call. (Operator Instructions) Please be advised that this conference call is being recorded. I would now like to hand the conference over to your speaker for today, Dr. Carlo Tanzi of Investor Relations. Carlo, please go ahead.
Thank you, and good morning. A press release announcing that Seres has entered into a license agreement with Nestlé Health Science, who we'll be referring to as Nestlé, to co-commercialize SER-109 became available at 7:00 a.m. Eastern Time this morning and can be found on the Investors & News section of the company's website.
I'd like to remind you that we'll be making forward-looking statements relating to the timing, enrollment and results of our clinical studies, regulatory approval, the promise and potential impact of SER-109, including the potential market size, any potential benefits of collaborating with Nestlé, potential
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)